Nattokinase and serrapeptase are both proteolytic enzymes marketed for cardiovascular and anti-inflammatory support, and supplement brands increasingly sell them together in a single capsule. The appeal is intuitive: if each enzyme breaks down fibrin and other proteins through its own mechanism, stacking them might produce a stronger or broader effect than either alone. That logic deserves scrutiny before anyone acts on it.
This article explains what each enzyme does, where their mechanisms overlap and differ, what the current evidence actually supports (and does not), and the safety considerations that make this combination genuinely risky for certain people. No peer-reviewed human trial has tested this specific combination, so every claim about synergy below remains theoretical; the one published human report involving a combination product describes serious harm from misuse, and is covered under risks.
Key Takeaways
- Nattokinase degrades fibrin directly and, in lab and animal work, appears to raise tissue plasminogen activator activity [2][3][4]; serrapeptase works through direct proteolytic digestion of fibrin and inflammatory proteins via distinct mechanisms.
- The synergy argument for combining them is mechanistically plausible but has not been tested in human clinical trials: any strong efficacy claim about the stack goes beyond current evidence.
- Both enzymes have fibrinolytic activity; combining them raises legitimate additive bleeding risk, especially alongside warfarin, aspirin, clopidogrel, or other anticoagulants.
- Discontinue both supplements at least one week before surgery and discuss with your physician; do not substitute either enzyme for prescribed blood thinners without medical guidance.
- When choosing a product, look for FU activity labeling for nattokinase, enteric-coated serrapeptase, and third-party quality verification: milligram weight alone is not a reliable potency indicator.
What Nattokinase Is and How It Works
Nattokinase is a serine protease extracted from natto, a traditional Japanese food made by fermenting soybeans with Bacillus subtilis. A review reports intact nattokinase in the serum of healthy people after a single 2,000 FU capsule, but EFSA said the supplied data could not show whether active nattokinase is absorbed [5][6]. Once circulating, it degrades fibrin directly by cleaving specific peptide bonds within the fibrin mesh that forms blood clots.
Beyond direct fibrinolysis, nattokinase appears to upregulate the body’s own clot-dissolving system. In lab and animal work it appears to raise tissue plasminogen activator (tPA) activity, but a 3-year trial in 265 healthy adults found no effect on tPA antigen [2][3][4][7]. In rabbit and rat plasma tests nattokinase inhibited platelet aggregation, which suggests it may reduce platelet aggregation independently of its fibrinolytic effects, but this has not been shown in human trials [8][9]. Small trials have reported modest blood pressure changes, with mixed results: one found only a diastolic fall and a 3-year trial in 265 healthy adults found none. A single-dose study in 12 healthy men showed higher D-dimer, a marker of fibrin breakdown [10][11][7][12].
The FDA has not evaluated nattokinase as a treatment, cure, or preventive for any disease. It is sold in the United States as a dietary supplement, not a drug, and the evidence base, while promising in early studies, does not yet meet the standard required for a clinical recommendation.
What Serrapeptase Is and How It Works
Serrapeptase (also called serratiopeptidase) is a serine protease originally isolated from the bacterium Serratia marcescens found in the gut of the silkworm Bombyx mori. The silkworm uses the enzyme to dissolve its cocoon, and researchers identified its ability to break down non-living protein structures. It is now produced through microbial fermentation and sold as an oral supplement, most commonly in enteric-coated form to protect it from stomach acid.
Research note: In a non-randomized comparison, serrapeptase reduced ankle edema more than paracetamol, while pain control did not differ significantly [19].
Serrapeptase digests fibrin, mucoproteins, and necrotic tissue but does not directly stimulate the plasminogen activator pathway the way nattokinase does. Its proposed anti-inflammatory effects stem partly from its ability to break down bradykinin and other pain-mediating proteins, and from degrading the fibrin scaffold that can wall off areas of chronic inflammation. Some European and Japanese clinical research has examined serrapeptase for post-surgical swelling and sinusitis, though evidence quality is inconsistent and regulatory acceptance varies widely by country.
Like nattokinase, serrapeptase is not FDA-approved to treat any condition, and the human trial data is limited in scale and duration. Enteric coating matters significantly for oral bioavailability because stomach acid inactivates the enzyme.
The Case for Combining Them: Proposed Mechanisms of Synergy
The rationale offered for stacking nattokinase and serrapeptase is that their fibrinolytic mechanisms are partly complementary. Nattokinase works directly on fibrin and, in lab and animal work, may indirectly raise plasminogen activator activity [2][3]. Serrapeptase works primarily through direct proteolytic digestion of fibrin and inflammatory proteins without meaningfully activating the plasminogen pathway. In theory, combining them could produce additive fibrinolytic activity through two distinct routes simultaneously.
Serrapeptase’s additional ability to break down mucoproteins and necrotic debris is sometimes cited as a reason to stack it with nattokinase in protocols aimed at reducing biofilm or clearing areas of chronic inflammation. Nattokinase’s antiplatelet activity adds a third mechanism not shared by serrapeptase. Proponents argue this creates a broader enzymatic profile than either supplement alone.
It is important to be clear: there are no published human clinical trials specifically studying the nattokinase-serrapeptase combination as a paired intervention. The synergy argument is mechanistically plausible but remains theoretical. Anyone making strong efficacy claims about this specific stack is going beyond what current evidence supports.
Risks and Contraindications: Where This Gets Serious
Both enzymes have fibrinolytic and, in nattokinase’s case, antiplatelet activity. Combining two fibrinolytic agents produces a reasonable concern about additive or synergistic bleeding risk. This concern becomes significantly more serious when either enzyme is used alongside pharmaceutical anticoagulants or antiplatelets. Nattokinase must not be combined with warfarin, heparin, aspirin, clopidogrel, rivaroxaban, apixaban, or similar agents without direct physician supervision. The same caution logically extends to serrapeptase given its fibrinolytic action. For someone already on blood thinners, adding either supplement, let alone both, could increase bleeding risk unpredictably.
People scheduled for surgery should discontinue both supplements. At minimum, nattokinase should be stopped at least one week before any surgical or dental procedure. Consulting the treating physician or surgeon about serrapeptase on the same timeline is prudent. Bleeding events are not commonly reported in trial data, but case reports exist, including a cerebellar hemorrhage in a patient also taking aspirin and a fatal hemoperitoneum in a patient taking no anticoagulant (causation unproven), and long-term safety data are limited [13][14][15].
One published case shows how badly this category can go wrong outside of normal use. A man who had read about an oral serrapeptase-and-nattokinase supplement as a treatment for Peyronie’s disease injected it into a vessel in his own arm rather than swallowing it, developed vascular necrosis, and ultimately required amputation above the elbow.[1] The route of administration, not the stack, is what produced that outcome, and nothing in it implies an oral capsule carries a comparable risk. It is included because it is the only peer-reviewed human report involving this combination, and because it shows how far people will go with enzymes marketed for “circulation” when the marketing outruns the evidence.
Other populations who should consult a physician before using this combination include anyone with a bleeding disorder, a history of hemorrhagic stroke, peptic ulcers, or active gastrointestinal bleeding. Pregnancy and breastfeeding represent additional caution categories where human safety data is essentially absent. People taking fish oil, vitamin E, or other supplements with antiplatelet properties should also factor those into the cumulative picture.
What to Look for in Combination Products
If someone decides to use a nattokinase-serrapeptase combination product after reviewing the risks with a healthcare provider, product quality matters considerably. For nattokinase, activity is measured in fibrinolytic units (FU); daily doses across the trials in one meta-analysis ranged from 1,200 to 8,000 FU, an uncontrolled cohort from the tablet maker used 10,800 FU, and a review notes that FU labels from different assay methods may not be directly comparable; optimal dosing for any specific purpose has not been established [4][16][17]. Look for products that list FU activity rather than milligrams alone, since milligrams without activity units tell you nothing useful about potency.
For serrapeptase, activity is measured in serrapeptase units (SPU) or international units (IU). Enteric coating is not optional: it is necessary for the enzyme to survive stomach acid and reach the small intestine where it can be absorbed. Products that do not specify enteric coating for their serrapeptase component should be viewed skeptically.
Third-party testing by organizations such as NSF International, USP, or ConsumerLab provides meaningful quality assurance that the product contains what the label claims and is free from heavy metal contamination. This matters particularly for enzyme supplements, where activity can be degraded by poor manufacturing conditions or storage. A product listing both FU and SPU activity, using enteric delivery for the serrapeptase component, and carrying third-party verification gives the most confidence in what you are actually taking.
Honest Summary of Where the Evidence Stands
Nattokinase has a more developed human evidence base than serrapeptase. Small trials have documented changes in fibrinolysis markers in human plasma and reported modest blood pressure changes, but the longest trial found no effect on blood pressure, artery thickening or laboratory measures [12][10][7]. These are real signals, but the trials are short-term, involve small numbers of participants, and have not yet established optimal doses, long-term safety profiles, or which patient populations benefit most.
In human studies serrapeptase helped swelling more than pain, and the funding matters
Swelling better, pain unchanged
In 133 patients after third molar surgery, reported pain did not differ significantly from placebo, but swelling and jaw opening improved more over 5 days. A drug company funded the trial.
Less ankle swelling than paracetamol
In 76 people with ankle sprains over 10 days, serrapeptase reduced ankle swelling more than paracetamol, while pain control did not differ significantly.
Pain scores fell faster
In 813 completers of 850 orthopedic trauma patients, pain scores fell faster with serrapeptase, a mean difference of 1.4 points by day 15. Doctors chose the treatment and the manufacturer funded the study.
Serrapeptase looks more useful for swelling than for pain, and none of this tests it alongside nattokinase.
Each card is a different study in different patients, so the results are not directly comparable. Source: Tamimi et al., BMC oral health 2021; Stamati et al., Journal of clinical orthopaedics and trauma 2024; Dilshad Hussain et al., Journal of Medicine and Life 2026.
Embed this chart
Free to reuse on your site. Copy the code below; please keep the credit link.
Serrapeptase’s human evidence is thinner and more contested. Some European studies suggest benefit for post-surgical swelling and sinus conditions; other reviews characterize the evidence as insufficient for clinical conclusions. The combination has not been studied as a paired intervention in human trials at all.
In one randomized trial of 133 patients after third molar surgery, serratiopeptidase did not significantly change reported pain compared with placebo, but it gave better swelling and jaw-opening improvement over 5 days; the trial was funded by a drug company [18].
Anyone approaching this stack should do so with realistic expectations: it is not a proven cardiovascular therapy, it is not a replacement for prescribed anticoagulation, and it carries real risks that are easy to underestimate because both products are sold over the counter as supplements. The most responsible path is a conversation with a physician who knows your full medication list before starting.
🛒 Where to Buy Nattokinase
- Doctor’s Best Nattokinase 2,000 FU
capsules, 100 mg NSK-SD per vcap (2,000 FU): Nattokinase from an established supplement brand; vegetarian capsules; 90 count - NOW Foods Nattokinase 100 mg
capsules, 100 mg per vcap (2,000 FU): Mainstream brand with third-party GMP-certified manufacturing; affordable entry-level option; 90 vcaps; widely available - Source Naturals Nattokinase 100 mg
capsules, 100 mg per tablet (2,000 FU): Long-established supplement brand; competitive pricing at 60 tablets; good for budget-conscious buyers familiar with the brand - Healthy Origins Nattokinase 2,000 FU
capsules, 100 mg per vcap (2,000 FU): Best cost-per-serving option on Amazon; 180 vcap bottle; uses NSK-SD ingredient; popular bulk buy for long-term users
As an Amazon Associate we earn from qualifying purchases. Nattokinase is sold on an enzymatic activity claim, and independent testing has repeatedly found bottles delivering well under their labelled potency. Check that the label states fibrinolytic units (FU) per capsule rather than milligrams alone, and prefer a brand that will supply a batch-specific certificate of analysis showing the measured FU result for that lot, since GMP certification alone does not verify it.
A Note on the Evidence
Most human research on nattokinase consists of small, short-term trials, and serrapeptase’s evidence base is similarly limited; no clinical trial has studied the two together as a combination. Anyone with a bleeding disorder, cardiovascular disease, history of stroke, or current use of anticoagulant or antiplatelet medications should consult a physician before using either supplement, and must not use both without medical guidance. This article is informational and does not constitute medical advice.
Frequently Asked Questions
Do nattokinase and serrapeptase work the same way?
No. Nattokinase degrades fibrin directly and also appears, in lab and animal studies, to raise plasminogen activator activity and to reduce platelet aggregation [2][3][8]. Serrapeptase works through direct proteolytic digestion of fibrin, mucoproteins, and necrotic tissue without meaningfully activating the plasminogen pathway. Their mechanisms overlap in outcome but differ in route.
Is there clinical proof that taking both together is more effective than taking one alone?
No human clinical trials have tested the nattokinase-serrapeptase combination as a paired intervention. The synergy rationale is based on mechanistic reasoning from studies of each enzyme individually, not from direct evidence of their combined efficacy.
Can I take this combination if I am already on blood thinners?
No, not without explicit physician approval. Nattokinase has documented fibrinolytic and antiplatelet activity; combining it with warfarin, heparin, aspirin, clopidogrel, or direct oral anticoagulants could increase bleeding risk unpredictably. The same caution applies to serrapeptase given its fibrinolytic properties.
Why does serrapeptase need to be enteric coated?
Serrapeptase is a protein-based enzyme that is inactivated by stomach acid. Without an enteric coating that resists dissolving until the pill reaches the less acidic environment of the small intestine, the enzyme is destroyed before it can be absorbed. Products without enteric coating for their serrapeptase component are unlikely to deliver active enzyme to the bloodstream.
How soon before surgery should I stop taking these supplements?
Nattokinase should be discontinued at least one week before any surgical or dental procedure due to its fibrinolytic and antiplatelet effects. Applying the same one-week timeline to serrapeptase is a reasonable precaution. Always inform your surgeon or anesthesiologist about all supplements you take.
Are these supplements FDA approved?
Neither nattokinase nor serrapeptase is FDA-approved to treat, cure, or prevent any disease. Both are sold in the United States as dietary supplements under regulations that do not require proof of efficacy before sale. The FDA has not evaluated either enzyme for therapeutic use.
References
- Yang et al. Vascular necrosis of the upper extremity after self-treatment for Peyronie’s disease. Sexual Medicine (2021). PMID 33307341
- Tetsumei Urano et al. The Profibrinolytic Enzyme Subtilisin NAT Purified fromBacillus subtilis Cleaves and Inactivates Plasminogen Activator Inhibitor Type 1. Journal of Biological Chemistry (2001). PMID 11325965
- Hiroyuki Sumi et al. Natto Bacillus as an Oral Fibrinolytic Agent: Nattokinase Activity and the Ingestion Effect of Bacillus subtilis natto. Food Science and Technology Research (2004). doi:10.3136/fstr.10.17
- Li X et al. Nattokinase Supplementation and Cardiovascular Risk Factors: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Reviews in cardiovascular medicine (2023). PMID 39076715
- Weng Y et al. Nattokinase: An Oral Antithrombotic Agent for the Prevention of Cardiovascular Disease. International journal of molecular sciences (2017). PMID 28264497
- European Food Safety Authority (EFSA NDA Panel) Safety of fermented soybean extract NSK-SD as a novel food pursuant to Regulation (EC) No 258/97. European Food Safety Authority (EFSA NDA Panel) (2016). source
- Hodis HN et al. Nattokinase atherothrombotic prevention study: A randomized controlled trial. Clinical hemorheology and microcirculation (2021). PMID 33843667
- Ja‐Young Jang et al. Nattokinase improves blood flow by inhibiting platelet aggregation and thrombus formation. Laboratory Animal Research (2013). PMID 24396387
- Jae-Bum Kim et al. Evaluation of Nattokinase for Antithrombotic Effect and Pharmacological Efficacy by a Biological Test and Clinical Trial. KSBB Journal (2011). doi:10.7841/ksbbj.2011.26.5.393
- Kim JY et al. Effects of nattokinase on blood pressure: a randomized, controlled trial. Hypertension research : official journal of the Japanese Society of Hypertension (2008). PMID 18971533
- Jensen GS et al. Consumption of nattokinase is associated with reduced blood pressure and von Willebrand factor, a cardiovascular risk marker: results from a randomized, double-blind, placebo-controlled, multicenter North American clinical trial. Integrated blood pressure control (2016). PMID 27785095
- Yuko Kurosawa et al. A single-dose of oral nattokinase potentiates thrombolysis and anti-coagulation profiles. Scientific Reports (2015). PMID 26109079
- Chang YY et al. Cerebellar hemorrhage provoked by combined use of nattokinase and aspirin in a patient with cerebral microbleeds. Internal medicine (Tokyo, Japan) (2008). PMID 18310985
- Lintu Ramachandran et al. Nattokinase-Associated Hemoperitoneum in an Elderly Woman. Cureus (2021). PMID 35003944
- Maria-Zinaida Dobre et al. Navigating the Effects of Anti-Atherosclerotic Supplements and Acknowledging Associated Bleeding Risks. International Journal of Molecular Sciences (2025). PMID 41155474
- Chen H et al. Effective management of atherosclerosis progress and hyperlipidemia with nattokinase: A clinical study with 1,062 participants. Frontiers in cardiovascular medicine (2022). PMID 36072877
- Yuan Li et al. Biotechnology, Bioengineering and Applications of Bacillus Nattokinase. Biomolecules (2022). PMID 35883536
- Tamimi Z et al. Efficacy of serratiopeptidase after impacted third molar surgery: a randomized controlled clinical trial. BMC oral health (2021). PMID 33653320
- Stamati A et al. Efficacy and safety of serrapeptase on ankle sprain cases: A single center prospective comparative study. Journal of clinical orthopaedics and trauma (2024). PMID 39324023
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.
